MA43042A - Composition aqueuse d'apomorphine pour une administration sous-cutanée - Google Patents
Composition aqueuse d'apomorphine pour une administration sous-cutanéeInfo
- Publication number
- MA43042A MA43042A MA043042A MA43042A MA43042A MA 43042 A MA43042 A MA 43042A MA 043042 A MA043042 A MA 043042A MA 43042 A MA43042 A MA 43042A MA 43042 A MA43042 A MA 43042A
- Authority
- MA
- Morocco
- Prior art keywords
- apomorphine
- aqueous composition
- subcutaneous administration
- subcutaneous
- administration
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
- A61K38/063—Glutathione
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Psychiatry (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Hospice & Palliative Care (AREA)
- Gynecology & Obstetrics (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15187194 | 2015-09-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA43042A true MA43042A (fr) | 2018-08-08 |
Family
ID=54249338
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA043042A MA43042A (fr) | 2015-09-28 | 2016-09-28 | Composition aqueuse d'apomorphine pour une administration sous-cutanée |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20180280465A1 (fr) |
| EP (1) | EP3355887A1 (fr) |
| AU (1) | AU2016333486B2 (fr) |
| CA (1) | CA2999675C (fr) |
| MA (1) | MA43042A (fr) |
| WO (1) | WO2017055337A1 (fr) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2979688A1 (fr) | 2014-08-01 | 2016-02-03 | Britannia Pharmaceuticals Limited | Composition contenant de l'apomorphine et un cation de métal divalent |
| WO2023012736A1 (fr) * | 2021-08-05 | 2023-02-09 | Zydus Lifesciences Limited | Compositions pharmaceutiques stables d'apomorphine |
| JP2024531685A (ja) * | 2021-09-12 | 2024-08-29 | ジーエムピー・バイオテクノロジー・リミテッド | 神経障害の処置 |
| WO2023172649A1 (fr) * | 2022-03-11 | 2023-09-14 | Alexza Pharmaceuticals, Inc. | Triméthanolate de chlorhydrate d'apomorphine, ses polymorphes et ses utilisations |
| WO2023242355A1 (fr) | 2022-06-15 | 2023-12-21 | Ever Neuro Pharma Gmbh | Promédicaments d'apomorphine et leurs utilisations |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6121276A (en) | 1994-04-22 | 2000-09-19 | Pentech Pharmaceuticals, Inc. | Apomorphine-containing dosage forms for ameliorating male erectile dysfunction |
| US5562917A (en) | 1994-12-23 | 1996-10-08 | Pentech Pharmaceuticals, Inc. | Transdermal administration of apomorphine |
| SE0102036D0 (sv) | 2001-06-08 | 2001-06-08 | Axon Biochemicals Bv | Pharmaceutical formulation for the efficient administration of apomorphine, 6aR- (-) -N- Propyl- norapomorphine and their derivatives and pro-drugs thereof |
| GB0509317D0 (en) | 2005-05-06 | 2005-06-15 | Clarke Anthony | Pharmaceutical formulation of apomorphine |
| GB0715285D0 (en) | 2007-08-06 | 2007-09-12 | Britannia Pharmaceuticals Ltd | Improvements in or relating to powdered medicaments for nasal delivery |
| GB0721394D0 (en) | 2007-10-31 | 2007-12-12 | Vectura Group Plc | Compositions for trating parkinson's disease |
| EP2545905A1 (fr) | 2011-07-11 | 2013-01-16 | Britannia Pharmaceuticals Limited | Nouvelle composition thérapeutique contenant de l'apomorphine en tant que principe actif |
| CA2875446A1 (fr) * | 2012-06-05 | 2013-12-12 | Neuroderm Ltd. | Compositions comprenant de l'apomorphine et des acides organiques, et leurs utilisations |
-
2016
- 2016-09-28 EP EP16784139.4A patent/EP3355887A1/fr active Pending
- 2016-09-28 WO PCT/EP2016/073086 patent/WO2017055337A1/fr active Application Filing
- 2016-09-28 AU AU2016333486A patent/AU2016333486B2/en active Active
- 2016-09-28 US US15/763,716 patent/US20180280465A1/en not_active Abandoned
- 2016-09-28 MA MA043042A patent/MA43042A/fr unknown
- 2016-09-28 CA CA2999675A patent/CA2999675C/fr active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20180280465A1 (en) | 2018-10-04 |
| CA2999675C (fr) | 2023-10-17 |
| AU2016333486B2 (en) | 2022-02-03 |
| WO2017055337A1 (fr) | 2017-04-06 |
| AU2016333486A1 (en) | 2018-04-19 |
| EP3355887A1 (fr) | 2018-08-08 |
| CA2999675A1 (fr) | 2017-04-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA41265A (fr) | Compositions pour administration de médicaments iléo-jéjunal. | |
| CR20160456A (es) | Compuestos de heteroarilo o arilo bibíclicos fusionados | |
| MA40587A (fr) | Composés d'aminopyrimidinyle en tant qu'inhibiteurs de jak | |
| MA55194A (fr) | Composés hétérocycliques en tant qu'immunomodulateurs | |
| MA42990A (fr) | Composés utiles en tant qu'immunomodulateurs | |
| EP3442601A4 (fr) | Administration de vecteur de virus adéno-associé de micro-arn-29 pour traiter une dystrophie musculaire | |
| EP3380062A4 (fr) | Compositions pour le traitement des cheveux | |
| EP3280421A4 (fr) | Compositions pharmaceutiques pour thérapie combinée | |
| LT3116491T (lt) | Terapiškai aktyvių junginių farmacinės kompozicijos | |
| DK3532029T3 (da) | Flydende farmaceutisk sammensætning | |
| MA43042A (fr) | Composition aqueuse d'apomorphine pour une administration sous-cutanée | |
| BR112017008125A2 (pt) | redução da viscosidade de formulações farmacêuticas | |
| EP3310439A4 (fr) | Compositions pharmaceutiques pour des applications anesthésiologiques | |
| LT3307267T (lt) | Išsėtinės sklerozės gydymas | |
| EP3365403A4 (fr) | Combinaison d'inhibiteurs de cobalt pour un bombage amélioré | |
| FR3013222B1 (fr) | Extrait d'algues pour son utilisation en tant qu'agent immunomodulateur | |
| EP2948134A4 (fr) | Compositions pour une administration transdermique d'inhibiteurs de mtor | |
| EP3378484A4 (fr) | Composition pharmaceutique pour le traitement de la fibrose cardiaque | |
| MA43230A (fr) | Méthodes et compositions pour le traitement d'une épidermolyse bulleuse | |
| MA43570A (fr) | Thérapie génique pour traiter l'hypercholestérolémie familiale | |
| GB2548424B (en) | Liquid pharmaceutical composition of clonidine | |
| EP3626256C0 (fr) | Composition pour le traitement des lésions tissulaires | |
| DK3313370T3 (da) | Oftalmologisk farmaceutisk sammensætning | |
| GB201718468D0 (en) | Stable liquid pharmaceutical compositions of bortezomb | |
| EP3355894A4 (fr) | Composition pour le maintien de la dominance de lactobacillus |